PRESS-RELEASE ·Filed Sep 17, 2026
Press release · Announcement
Actionable Insight • Neutral
This is a routine presentation with no material new information. Monitor for future clinical data releases or regulatory filings to assess pipeline progress.
Latest settled — T+20d
CMND ▼ -6.47% at T+20d
NEUTRAL call -6.47% · α vs SPY -7.92% · entry $6.86 → $6.42
Latest observation: T+26 +48.99% FF3 residual α
T+1d
-6.88%
call -6.88% · α -7.01%
$6.39
settled 6w ago
T+5d
-5.59%
call -5.59% · α -6.44%
$6.48
settled 5w ago
T+20d
-6.47%
call -6.47% · α -7.92%
$6.42
settled 12d ago
T+60d
Pending
in 6w
Price Chart
Loading chart...
Executive Summary
Clearmind Medicine's Chief of Global Impact presented insights from the company's clinical trial at Yale and Johns Hopkins, discussing patient access. No financial data, clinical results, or regulatory milestones were disclosed in this press release.
Key Facts
- Mary-Elizabeth Gifford, Chief of Global Impact, spoke on patient access at an unspecified event.
- Shared insights from Clearmind's clinical trial conducted at Yale and Johns Hopkins.
- No financial figures, clinical data, or regulatory updates were provided.
Financial Impact
No financial impact disclosed.
Risk Factors
- No clinical results or regulatory milestones were announced, limiting actionable information.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3363882 |
63 reports for CMND
53% Hit rate @ T+60 Went positive at some point 16 of 21 best @ T+60▲ +75.73%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $5.87 (+2.17%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $5.87 (−5.78%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $5.87 (−11.06%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.87 (−11.06%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.87 (+590.59%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.87 (+590.59%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.87 (−14.48%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.87 (+521.82%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $5.87 (+469.90%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $5.87 (−406.03%) |
Showing 10 of 63
US Market Status
Market Closed — Opens Wed (13h 21m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers